Researchers develop a new mRNA vaccine model that may offer long-lasting protection with smaller doses and faster production timelines.
A new study by the University of Pittsburgh School of Public Health and Penn State University has shown progress toward building mRNA vaccines that are easier to produce and more adaptable to changing viruses. Published in npj Vaccines, the research outlines an experimental COVID-19 vaccine model using what’s called a trans-amplifying mRNA platform.
Unlike conventional mRNA vaccines that use a single strand of code to trigger immunity, this approach splits the vaccine into two parts: one carrying the antigen—the part that trains the body to recognize the virus—and the other containing a replicase sequence that helps produce more of the antigen once inside the body. The key advantage is that the replicase can be made ahead of time and stored, giving developers a head start when responding to new viral threats.
To make the vaccine more effective across multiple variants, researchers looked at all known spike protein sequences of the SARS-CoV-2 virus. From these, they built a “consensus spike protein,” designed to target features that remain the same across strains. This method could improve the chances of the vaccine offering broader, longer-lasting protection without frequent updates.
Tests in mice showed strong immune responses to several variants. In addition to this, the vaccine required a much smaller dose—up to 40 times less than current mRNA vaccines—making it more affordable and easier to scale.
The team believes this method could be applied to other viruses, including bird flu, which also mutate quickly and carry the risk of future outbreaks. The next steps will involve adapting the technology to other use cases and evaluating its effectiveness in larger trials. This research could shape the next wave of mRNA vaccine development by focusing on flexibility, speed, and reduced cost.
